1558 results about "Tetra" patented technology

The present invention includes hyaluronic acid complexes of a monovalent alkali metal salt of hyaluronic acid and a tetra alkyl ammonium halide that are suitable for incorporation with tissue scaffolds that are suitable for use in repair and / or regeneration of muscoloskeletal tissue and that include a biodegradable, porous substrate made from a biodegradable, hydrophobic polymer, where the hyaluronic acid complex is substantially insoluble in water at room temperature, yet soluble in mixtures of organic and aqueous solvents in which the selected hydrophobic polymer is soluble.

The present invention discloses a method and apparatus for sterilizing containers with gas-phase hydrogen peroxide and heat on a linear form, fill and seal packaging machine. A partially formed container is subjected to multiple applications of gaseous hydrogen peroxide and hot air within a sterilization tunnel. The sterilization tunnel is maintained at a temperature greater than the condensation temperature of hydrogen peroxide. The present invention sterilizes the container allowing for filling of the container with a high acid product such as orange juice for ambient distribution. The container may be any number of possibilities such as TETRA REX TM gable top cartons, plastic bottles, and the like. The invention allows for the efficacious use of hydrogen peroxide gas having a concentration of up to 53%.

The present invention relates to large scale preparation of LNA phosphoramidites using a 2-cyanoethyl-N,N,N′,N′-tetra-substituted phosphoramidite and a nucleophilic activator, e.g. 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite and 4,5-dicyanoimidazole. The method is faster and more cost efficient that previously known methods.

A process for making a relatively low molecular weight, mid-range vinylidene content PIB polymer product comprising a liquid phase polymerization process conducted in a loop reactor at a temperature of at least 60° F. using a BF3 / methanol catalyst complex and a contact time of no more than 4 minutes. At least about 90% of the PIB molecules present in the product comprise alpha or beta position isomers. The vinylidene (alpha) isomer content of the product may range from 20% to 70% thereof, and the content of tetra-substituted internal double bonds is very low, advantageously no more than about 10%, preferably less than about 5% and ideally less than about 1-2%.

The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphate salts. The present invention also provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.

The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five M. tuberculosis antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.

The present invention provides embolic compositions, methods, and devices for embolizing a body lumen. In one embodiment, the embolic composition comprises a mixture of polyethylene glycol diacrylate (PEGDA), pentaerythritol tetra(3-mercaptopropionate), and a physiologically acceptable buffer solution.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.

One aspect of the present invention is a light emitting element having a layer including an aromatic hydrocarbon and a metal oxide between a pair of electrodes. The kind of aromatic hydrocarbon is not particularly limited; however, an aromatic hydrocarbon having hole mobility of 1×10−6 cm2 / Vs or more is preferable. As such aromatic hydrocarbon, for example, 2-tert-butyl-9,10-di(2-naphthyl)anthracene, anthracene, 9,10-diphenylanthracene, tetracene, rubrene, perylene, 2,5,8,11-tetra(tert-butyl)perylene, and the like are given. As the metal oxide, a metal which shows an electron-accepting property to the aromatic hydrocarbon is preferable. As such metal oxide, for example, molybdenum oxide, vanadium oxide, ruthenium oxide, rhenium oxide, and the like are given.

An object of the present invention is to provide a process capable of producing a self-assembling peptide derivative that is useful in the fields of regenerative medicine and surgery in large quantities and in an economical and efficient manner. In particular, provided is a production process employing a combination of (i) a step of convergently constructing a sequence with use of a common repeating unit consisting of a specific amino acid sequence and (ii) a step of first isolating the peptide derivative as a disulfuric acid salt, a tetramethanesulfonic acid salt or a tetra(trifluoroacetic acid (TFA) salt), and then subjecting the peptide salt to a salt exchange reaction to yield a tetrahydrochloric acid salt.

Disclosed herein is novel highly stable, crystalline porphyrin containing covalent organic frameworks and their synthesis using Schiff base reaction which are hydrophobic in nature having good selectivity towards alcohol uptake at low pressure over water. Particularly, present invention provides novel highly stable, porous covalent organic frameworks (COFs) comprising porphyrin linked hydroxyl aromatic compound by intramolecular O—H—N═C bonding; wherein porphyrin is tetra(p-amino-phenyl)porphyrin (Tph) and hydroxyl aromatic compound is selected from group consisting of Triformylphloroglucinol (Tp), 2,5-dihydroxyterephthalaldehyde (Da).

A composition comprising: polyethylene; as a scorch inhibitor, 2,4-diphenyl-4-methyl-1-pentene; as a cure booster, 3,9-divinyl-2,4,8,10-tetra-oxaspiro[5.5]undecane; and an organic peroxide.

The invention is based on the reaction of recombinagenic oligonucleotides in a cell-free system containing a cytoplasmic cell extract and a test duplex DNA on a plasmid. The reaction specifically converts a mutant kanr gene to recover the resistant phenotype in transformed MutS, RecA deficient bacteria and allows for the rapid and quantitative comparison of recombinagenic oligonucleobases. Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacement of a tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2'-O-methyl-uridine, to link the two strands of the Duplex Mutational Vector and removal of the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern a reaction mixture containing a recombinagenic oligonucleobase, a cell-free enzyme mixture and a duplex DNA containing a target sequence. In yet an alternative embodiment, the invention concerns the use of such mixture to test improvements in recombinagenic oligonucleobases, as well as to test the effects of compounds on the activity of the cell-free enzyme mixture and also to make specific changes in the target DNA sequence.

The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.

The invention discloses a gold complex catalyst, and particularly relates to a non-mercury catalyst which is applicable to synthesizing vinyl chloride by acetylene hydrochlorination, and a preparation method of the non-mercury catalyst. The non-mercury catalyst comprises potassium aurate tetra-thiocyanate taken as a main active component, one or a combination of more than two of potassium chloride, copper chloride, cobalt chloride and zinc chloride taken as auxiliary active components, and carrier activated carbon, wherein gold complex accounts for 0.1-2.5% of the weight of the catalyst, and the auxiliary active components account for 0.05-15% of the total weight of the catalyst. According to the gold complex catalyst prepared by the invention, the gold content is lower, so that the cost of noble metal catalyst can be remarkably reduced; and the novel non-mercury catalyst is good in activity, high in stability and strong in selectivity. The gold complex catalyst has the advantages of being simple in production technology, short in production cycle and environment-friendly.

The present invention describes the use of porous metal oxides for the preparative purification of antibodies and biomolecules within a range of particle physical characteristics. Typically, particles from 15 to 100 microns in average diameter with pores sizes ranging from 400 to 600 angstroms and surface areas from 10 to 50 square meters per gram, and pore volumes from 0.1 to 0.4 mL / gram can be used for purification processes. The metal oxide particles that fall within this range of physical properties show enhanced utility and greater chromatographic capacity for antibodies than materials oxide particles falling outside of this range. Metal oxides such as zirconia, titania and alumina can all be modified with a multi-Lewis base moiety such as an organophosphate ethylenediamine-N,N-tetra(methylenephosphonic) acid (EDTPA), to produce a bio-compatible purification media for, biomolecules.

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

The invention discloses a tetra-rotor aircraft attitude obtaining method by use of a three-order approximation Picard quaternion. The method comprises the following steps: (1), according to the three-order approximation Picard quaternion, performing attitude solution so as to prevent a gyroscope from integration accumulative errors and reduce differential amplification of noise; and (2), performing Kalman filtering on an attitude angle obtained through the solution so as to effectively filter sensor measuring errors caused by vibration of a tetra-rotor aircraft body and obtain a more accurate attitude angle. The attitude solution method provided by the invention can perform accurate attitude estimation on a miniaturized tetra-rotor aircraft.

This invention is an organic silicon modification acrylic acid ester emulsion that used to environment temperature crosslinking water craft coating. The feature is that it is made by the following way, organosilicon prepolymer is synthesized first, then it is reacted with tetra ethyl ortho silicate, silicon dioxide nanometer particle of modifying surface is synthesized by sol-gel technique. Seed emulsion got by seed emulsion concentrical technique is core, compound consisted by nonsaturated organosilicon monomer, hard monomer, soft monomer and function monomer, and the silicon dioxide nanometer particle said above is shell, then anorganic nanometer particle modified silicon abicin emulsion is got through nucleocapsid trough polymer network polyreaction. The preparing method includes following procedures (1) synthesis of organic silicon prepolymer. (2) Preparing of silicon dioxide nanometer particle. (3) Preparing of seed emulsion. (4) Synthesis of silicon abicin emulsion, then this product is got. Abrasion resistant quality, alkali resistance, water resistance, weather resistance, soiling resistance of the product after film forming is greatly improved.

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

The present invention belongs to the technical field of biological pharmacy, and in particular relates to a preparation and purification method of tetra-hydroxyl xanthone mango aglycone (norathyriol), and an application thereof in hypoglycemic medicine. Based on biological experiments, mango glycoside is used as raw material; under the condition with phenol and hydroiodic acid, carbon-carbon bonds are broken to produce the crude product of mango aglycone; the crude product is separated and purified through silica gel column chromatography so that the mango aglycone is separated; the yield rate reaches 12 percent, the purity is higher than 95 percent, and the reproduction performance is good; the IGTT of C57BL / 6 normal mice is effectively improved with the norathyriol; and simultaneously the quantity of insulin secretion induced by glucose in vivo for the C57BL / 6 normal mice can be improved with the norathyriol. Therefore, the mango aglycone can be applied for preparation of hypoglycemic medicine.

Compositions and methods of their use to adhere a variety of materials together are disclosed herein. The compositions include at least tetra calcium phosphate, an effective amount of a compound that is structurally similar to phosphoserine, and can be mixed with an aqueous solution. The compositions provide adhesive and cohesive strength in both wet and dry environments and exhibit significant bond strength upon curing.

The invention discloses a polyolefin wood-plastic composite material. The polyolefin wood-plastic composite material is prepared by blending and extruding the following components in parts by weight: 20 to 80 parts of polyolefin resin, 20 to 80 parts of plant fiber powder, 2 to 8 parts of compatilizer, 1 to 8 parts of lubricant, and 0.1 to 1 part of antioxygen, wherein the lubricant includes pentaerythritol tetra-benzoate. The composite material has the balance torque of 3.2 to 8.4N.M, bending strength of 30.1 to 66.3MPa, and bending modulus of (0.80-22.6)*10<4>MPa. The invention also discloses a preparation method of the polyolefin wood-plastic composite material. The ester bond of the pentaerythritol tetra-benzoate contained in the wood-plastic composite material and the hydroxyl of the plant fibers can produce high hydrogen bond effect, so that the plant fibers can be promoted to be uniformly dispersed, the filling amount can be increased, the product cost is reduced, the defect on the appearance of the product is avoided, the melting and extruding efficiency is improved, and the bending performance and water absorbing performance of the material are improved; and the polyolefin wood-plastic composite material can be used as the high-level polyolefin wood-plastic composite material to be widely applied in the fields such as indoor and outdoor decoration and construction industry.

The invention comprises a substrate for detection of micro-organisms, wherein said substrate comprises a set of molecular markers linked, optionally with linker molecules or moeieties, to a di-, or tripeptide consisting of amino acids X1 and X2, or X1, X2 and X3, in which one of them, for example X1, is a D-amino acid and the others, for example X2 and X3, may be any D- or L-amino acid. Said substrate preferably is used for the detection of Bacillus anthracis. Alternatively, the invention is directed to a substrate for detection of micro-organisms, more specifically P. aeruginosa, wherein said substrate comprises a set of molecular markers linked, optionally with linker molecules or moeities to a tri- tetra or pentapeptide consisting of glycine amino acids. The invention further comprises methods for detection of micro-organisms, specifically Bacillus anthracis and Pseudomonas aeruginosa, with the substrates of the invention and use of the substrate(s) in such a method.

The present invention discloses a porphyrin derivative with large substituent and its pharmaceutical acceptable salt and its preparation method. The described porphyrin derivative is M-5,10,15,20-tetra[(N)-substituted-n-phenyl or heterocyclic radical] porphyrin, in which n represents 2,3 and 4 postion substitution, and M is one of Fe, Mn, Co, Ni, Cu Zn, Sn, Cr and V metal ions. Said invented porphyrin derivative has higher steric hindrance, and can effectively resist the combination of porphyrin with DNA, and can reduce the mutual transformation between the different isomers, reduce toxicity of porphyrin and raise its medicinal practicability. The described porphyrin derivative can be used as small molecular antioxidant for regulating concentration of peroxide between cells of human body or in cell.

Nickel silicide is formed on the basis of a gaseous precursor, such as nickel tetra carbonyl, wherein the equilibrium of the decomposition of this gas may be controlled to obtain a highly selective nickel silicide formation rate. Moreover, any etch step for removing excess nickel may be avoided, since only minute amounts of nickel may form on exposed surfaces, which may then be effectively removed by correspondingly shifting the equilibrium. Consequently, reduced process complexity, enhanced controllability and enhanced tool lifetime may be obtained.

A chitosen-quaternary ammonium salt nanoparticle as the carrier of protein-type medicine is prepared through dissolving chitosan-quaternary ammonium salt in distilled water, stirring while adding solution of sodium tripolyphosphate, cross-linking, centrifugal separation, and freeze drying. It has long relesing period (6 days).

The invention relates to polyimide containing a benzimidazole unit and a preparation method thereof. The polyimide has the following structural formula. The preparation method comprises the following steps of: firstly, performing the reaction on 2,6-disubstituted aniline and aldehyde under the acidic condition to generate a diamine compound 3,3',5,5'-tetra-substituted aromatic diamine; and then, after mixing the synthesized aromatic diamine and a heterocyclic diamine monomer 6-aminophenyl-2-aminobenzimidazole according to a certain ratio, performing the reaction on the mixture and a dianhydride monomer in an organic solvent to obtain the polyimide. The polyimide provided by the invention has excellent solubility property, can be dissolved in conventional solvents such as NMP (N-methyl-2-pyrrolidone) and DMAc (dimethyl acetamide), has excellent heat resistance and mechanical property and has excellent thermal properties of glass-transition temperature of over 410 DEG C, decomposition temperature of over 500 DEG C and the like.

Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.